GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Equity-to-Asset

SELLAS Life Sciences Group (FRA:RXK3) Equity-to-Asset : 0.60 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SELLAS Life Sciences Group's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €14.32 Mil. SELLAS Life Sciences Group's Total Assets for the quarter that ended in Sep. 2024 was €23.88 Mil.

The historical rank and industry rank for SELLAS Life Sciences Group's Equity-to-Asset or its related term are showing as below:

FRA:RXK3' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.28   Med: 0.38   Max: 0.77
Current: 0.6

During the past 13 years, the highest Equity to Asset Ratio of SELLAS Life Sciences Group was 0.77. The lowest was -1.28. And the median was 0.38.

FRA:RXK3's Equity-to-Asset is ranked worse than
56.22% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:RXK3: 0.60

SELLAS Life Sciences Group Equity-to-Asset Historical Data

The historical data trend for SELLAS Life Sciences Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Equity-to-Asset Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.61 0.77 0.23 -1.28

SELLAS Life Sciences Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -1.28 0.40 0.19 0.60

Competitive Comparison of SELLAS Life Sciences Group's Equity-to-Asset

For the Biotechnology subindustry, SELLAS Life Sciences Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Equity-to-Asset falls into.



SELLAS Life Sciences Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

SELLAS Life Sciences Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.314/5.703
=

SELLAS Life Sciences Group's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=14.319/23.881
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SELLAS Life Sciences Group  (FRA:RXK3) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


SELLAS Life Sciences Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines